Brief: BioXcel Therapeutics Q4 Basic EPS USD -3.57 Vs. IBES Estimate USD -6.22
27/03/2025 11:00
Mar 27 (Reuters) - BioXcel Therapeutics Q4 net income USD -10.859 million vs. IBES estimate USD -18.9 million. Q4 operating income USD -10.493 million vs. IBES estimate USD -16.2 million Q4 revenue USD 366 thousand vs. IBES estimate USD 706.7 thousand Q4 operating expenses USD 10.859 million
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty